Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

[1]  M. Momeny,et al.  Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells , 2017, Scientific Reports.

[2]  Kailv Sun,et al.  Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma , 2016, Oncology letters.

[3]  G. Basaran,et al.  Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. , 2016, Critical reviews in oncology/hematology.

[4]  P. Harari,et al.  Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models , 2015, Clinical Cancer Research.

[5]  H. Modjtahedi,et al.  Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers , 2015, British Journal of Cancer.

[6]  L. Hudson,et al.  Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells , 2015, PloS one.

[7]  C. Ferreira,et al.  Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target? , 2015, Cancer Chemotherapy and Pharmacology.

[8]  S. Iacobelli,et al.  Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines , 2015, Oncotarget.

[9]  P. Jänne,et al.  Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[10]  Prahlad T. Ram,et al.  Hematogenous metastasis of ovarian cancer: rethinking mode of spread. , 2014, Cancer cell.

[11]  C. Muller,et al.  High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer , 2014, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[12]  J. Engelman,et al.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.

[13]  A. Jimeno,et al.  Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Tebbutt,et al.  Targeting the ERBB family in cancer: couples therapy , 2013, Nature Reviews Cancer.

[15]  P. Leung,et al.  HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells. , 2013, Biochemical and biophysical research communications.

[16]  A. Pandiella,et al.  HER3 overexpression and survival in solid tumors: a meta-analysis. , 2013, Journal of the National Cancer Institute.

[17]  F. Kabbinavar,et al.  Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab , 2013, PloS one.

[18]  R. Huang,et al.  Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. , 2012, Current drug targets.

[19]  K. Shen,et al.  The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. , 2012, Cancer epidemiology.

[20]  A. Ullrich,et al.  Inhibition of doxorubicin‐induced HER3‐PI3K‐AKT signalling enhances apoptosis of ovarian cancer cells , 2012, Molecular oncology.

[21]  Keunchil Park,et al.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Christensen,et al.  Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib , 2012, Molecular Cancer Therapeutics.

[23]  T. Tan,et al.  Abstract 2979: Epithelial-mesenchymal gene expression signature defines clinically relevant subtypes in epithelial ovarian cancer , 2012 .

[24]  Ping Yang,et al.  FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells , 2012, Acta Pharmacologica Sinica.

[25]  P. Yue,et al.  Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells , 2011, Oncogene.

[26]  Q. Sheng,et al.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer , 2011, British Journal of Cancer.

[27]  C. Rancourt,et al.  Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells , 2011, British Journal of Cancer.

[28]  F. Spinella,et al.  Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells , 2011, Clinical Cancer Research.

[29]  P. Jänne,et al.  Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors , 2011, Clinical Cancer Research.

[30]  Helen X. Chen,et al.  Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. , 2010, Gynecologic oncology.

[31]  Y. Shukla,et al.  Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells. , 2010, Biochemical pharmacology.

[32]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[33]  D. Wheeler,et al.  Mechanisms of resistance to HER family targeting antibodies. , 2010, Experimental cell research.

[34]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[35]  S. Steinberg,et al.  Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 , 2010, Clinical Cancer Research.

[36]  G. Mills,et al.  Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges , 2009, Journal of oncology.

[37]  Ituro Inoue,et al.  Gene expression profiling of advanced‐stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis , 2009, Cancer science.

[38]  J. Hartman,et al.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. , 2009, International journal of oncology.

[39]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[40]  E. Lam,et al.  Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer , 2009, Molecular Cancer Therapeutics.

[41]  I. Sher,et al.  Autocrine VEGF‐A/KDR loop protects epithelial ovarian carcinoma cells from anoikis , 2009, International journal of cancer.

[42]  Paola Chiarugi,et al.  Anoikis: a necessary death program for anchorage-dependent cells. , 2008, Biochemical pharmacology.

[43]  P. Leung,et al.  Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. , 2008, Molecular endocrinology.

[44]  Hao Li,et al.  Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression , 2008, Nature Cell Biology.

[45]  M. Piccart-Gebhart,et al.  New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. , 2008, Critical reviews in oncology/hematology.

[46]  P. Ellis,et al.  Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor , 2008, Molecular Cancer Therapeutics.

[47]  A. Baron,et al.  Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. , 2008, Biochimica et biophysica acta.

[48]  A. Secord,et al.  Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[49]  D. Katsaros,et al.  Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  F. Schmidt.  Meta-Analysis , 2008 .

[51]  M. Meyerson,et al.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.

[52]  M. Quinn,et al.  Epithelial–mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm , 2007, Journal of cellular physiology.

[53]  H. Höfler,et al.  The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients , 2007, British Journal of Cancer.

[54]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Breuleux.  Role of heregulin in human cancer , 2007, Cellular and Molecular Life Sciences.

[56]  D. Fishman,et al.  Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. , 2007, Cancer research.

[57]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[58]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Jorma Isola,et al.  Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma , 2006, Journal of Molecular Medicine.

[60]  David L Rimm,et al.  Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer , 2005, Clinical Cancer Research.

[61]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[62]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[63]  J. Nesland,et al.  Snail, Slug, and Smad‐interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma , 2005, Cancer.

[64]  R. Burger,et al.  Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. , 2005, Cancer research.

[65]  Hans Clevers,et al.  FoxM1 is required for execution of the mitotic programme and chromosome stability , 2005, Nature Cell Biology.

[66]  C. Britten,et al.  Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. , 2004, Molecular cancer therapeutics.

[67]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Smyth,et al.  Neuregulin expression, function, and signaling in human ovarian cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  M. Sakai,et al.  HER2 Is Frequently Over‐expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab , 2002, Japanese journal of cancer research : Gann.

[70]  N. Takai,et al.  Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. , 2001, Cancer letters.

[71]  J. Surrey,et al.  Couples Therapy , 2000 .

[72]  A. Ullrich,et al.  Distinct characteristics of heregulin signals mediated by HER3 or HER4 , 1997, Journal of cellular physiology.

[73]  J. Lang,et al.  Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. , 1997, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[74]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[75]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[76]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[77]  I. Vergote,et al.  A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  E. Lam,et al.  FOXM1: From cancer initiation to progression and treatment. , 2012, Biochimica et biophysica acta.

[79]  M. Stack,et al.  Activated epidermal growth factor receptor in ovarian cancer. , 2009, Cancer treatment and research.

[80]  Z. Estrov,et al.  E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[82]  N. Dubrawsky.  Cancer statistics , 2022 .